New Antibodies to Interleukin-6 (IL-6)

Published: 31.03.2021
30 Mar, 2021
New Recombinant COVID-19 Related Antigens

Angiotensin converting enzyme 2 (ACE2) and SARS-CoV-2 Nucleoprotein fragment N47-A173 samples available

Read more
29 Mar, 2021
EFLM Cardiac Marker Award - Sponsored by HyTest

Call for nominations! We are delighted to let you know that we are sponsoring the EFLM-HyTest Cardiac Marker Award for remarkable scientific work in the field of cardiovascular diseases.

Read more
24 Feb, 2021
New Pair Recommendations for the Development of High-Sensitivity Troponin I Assays

Early diagnosis of acute myocardial infarction (AMI) as a life-threatening disorder is important for immediate evidence-based therapy. The cardiac troponin I (cTnI) is a gold standard and diagnostic cornerstone in the clinical assessment of AMI. It offers accurate and rapid AMI rule outs.

Read more
24 Feb, 2021
Meet HyTest China Team at CACLP Expo and Satellite Conference

Meet HyTest China team at the 18th China Association of Clinical Laboratory Practice Expo held at Chongqing International Expo Center, on 28-30 March.

Read more
28 Jan, 2021
COVID-19 Antibodies Update - New R&D Samples Available

New R&D samples available:
- Polyclonal anti-SARS-CoV-2 Nucleoprotein
- New anti-SARS-CoV-2 RBD clones

Read more
28 Jan, 2021
New Appointments in the Sales Team

We are delighted to introduce our latest team member, Outi Vilamo and Netta Keinänen was appointed as the new Sales and Marketing Director from the beginning of January 2021

Read more
28 Jan, 2021
Listen our Awarded AACC Poster

Our scientists presented an awarded poster at the virtual AACC 2020:
“Diverse Short-Term Natriuretic Response in Acute Decompensated Heart Failure Patients Undergoing Entresto™ Treatment"

Read more
28 Dec, 2020
HyTest Group Welcomes Juhana Rauramo as its New CEO

Juhana Rauramo will become the new CEO of HyTest Group Oy with effect from January 1, 2021. Juhana has proven to be a very valuable person for HyTest and he has agreed to take on a more extensive role regarding the management of the company. Meanwhile, Maria Severina, the Founder and CEO of the company for the last 26 years will continue as a board member for HyTest Group Oy and she will be available as a consultant to the company.
Juhana has been the CCO of HyTest and a member of the management team since September 2019.

Read more
21 Dec, 2020
Season's Greetings 2020

In this exceptional year we must make exceptional actions. Check our Season's Greetings video to you:

Read more
10 Dec, 2020
Meet HyTest Team at Virtual AACC Expo

Connect with our representative during the AACC virtual expo, taking place December 14–17. Schedule a meeting at our booth through the virtual platform or contact us already now and agree a meeting.

Our new Sales Manager Outi Vilamo will be also waiting to meet you there.


Read more
08 Dec, 2020
Update on COVID-19 Antibodies

We are pleased to let you know that we now have the first four anti-nucleoprotein antibodies available in their final forms.

Read more
03 Dec, 2020
New Podcasts related to BNP and NT-proBNP

Clinical Chemistry podcasts are highlighting selected articles in the journal. Now our scientists have been guests in the Clinical Chemistry podcasts related to their publications in the same journal.
Listen below the podcasts and learn more about our cardiac markers.

Read more
19 Nov, 2020
Meet us at AACC 2020 – Free Expo Passes Available

AACC’s Annual Scientific Meeting & Clinical Lab Expo, taking place December 14–17, will include many activities that you are used to experiencing in a live event: scientific sessions, poster presentations, an Expo showcase and networking opportunities.
If you or a representative of your company is planning to attend, we would welcome the opportunity to meet with you at our virtual booth.

Read more
23 Oct, 2020
Now Available! COVID-19 Related Monoclonal Antibodies

Our first COVID-19 related monoclonal antibodies are now available

Read more
01 Oct, 2020
Soon Available! COVID-19 Antibodies

Our first COVID-19 related monoclonal antibodies will be soon available: Ten antibodies specific to SARS-CoV-2 nucleoprotein and two antibodies specific to Spike (RBD) will be launched in 2-3 weeks.

Read more
01 Oct, 2020
Editorial: Relevance of an in-Depth Analysis of Molecular Heterogeneity of Circulating NT-proBNP

In the latest Clinical Chemistry editorial our scientist addresses an article about molecular heterogeneity of NT-proBNP/proBNP published in the same issue. In the editorial our scientist discusses the complexity of this circulating heart failure marker, current NT-proBNP assays and how ongoing research including the addressed article could affect the design of future NT-proBNP assays.

Read more
17 Sep, 2020
COVID-19 Antibodies – R&D Samples Available

We are pleased to let you know that we are developing several monoclonal antibodies specific to SARS-CoV2 nucleoproteins (Cat.# 3CV4) and to Spike RBD (Cat.# 3CV2).

Read more
17 Sep, 2020
HyTest Live Webinar - Diagnostics of COVID-19: Achievements, Challenges and Perspectives

By watching this webinar, you will learn about:
- transmission and clinical characteristics of SARS-CoV-2
- the existing testing methods for SARS-CoV-2, including nucleic acid testing, genome sequencing, serological testing for SARS-CoV-2 specific antibodies and antigen testing
- the principles, advantages and limitations of these testing methods
- safety precautions for handling different types of clinical specimens for SARS-CoV-2 detection

Read more
26 Aug, 2020
New Product! SARS-CoV-2 Nucleoprotein

HyTest’s SARS-CoV-2 Nucleoprotein (Cat.# 8COV3) is a full-length recombinant antigen that can be used in serology assays for the detection of COVID-19 specific antibodies.

Read more

Sign up to our newsletter

And be informed about new products and scientific findings

Thank you for your subscription!